secwatch.observer — SEC 8-K summary
======================================

Issuer:     Adaptive Biotechnologies Corp (ADPT)
CIK:        0001478320
Form:       8-K
Filed at:   2026-07-29T20:15:15+00:00
Accession:  0001193125-26-323753
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adaptive Biotechnologies Q2 revenue $71.6M (+22% YoY); MRD up 33%; raises FY MRD guidance; CSO transitions to consultant
--------------------------------------------------------------------------------

- Q2 revenue $71.6M (+22% YoY); MRD revenue $66.2M (+33% YoY); clonoSEQ volume 36,111 (+43% YoY).
- Net loss $39.9M (incl. $23.7M loss on OrbiMed settlement); adjusted EBITDA loss improved to $0.7M from $7.2M.
- Completed $345M zero-coupon convertible notes offering; repaid OrbiMed Purchase Agreement; cash $371.7M.
- Raised FY 2026 MRD revenue guidance to $268M-$278M (from $260M-$270M); total opex guidance narrowed to $350M-$355M.
- CSO and co-founder Harlan Robins transitions to strategic consultant role; no disagreements.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1478320/000119312526323753/0001193125-26-323753-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1478320/000119312526323753/adpt-20260724.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-323753

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer